Continuous vs Intermittent Meropenem Administration in Critically Ill Patients With Sepsis

This randomized clinical trial compares the effect of continuous administration of meropenem vs intermittent administration on a composite outcome of mortality

Related Keywords

Croatia ,Russia ,Milan ,Lombardia ,Italy ,Northern Ireland ,Craigavon ,United Kingdom ,Santarpino ,Campania ,Belfast ,Kazakhstan ,Italian ,Giovanni Landoni ,Baiardo Redaelli ,Christopher Seymour ,Aurobindo Pharma ,Edwards Lifesciences ,Italian Medicines Agency ,San Raffaele Scientific Institute ,Group Information ,Study Drug Administration ,Intermittent Administration Of Meropenem ,Sepsis Campaign ,Gilead Sciences ,Pfizer ,Department Of Anesthesia ,Umehara Memorial Foundation ,Pearson ,Orion Pharma Ltd ,Surviving Sepsis Campaign ,Continuous Infusion ,Intermittent Administration ,Critically Ill Patients ,Sequential Organ Failure Assessment ,Simplified Acute Physiology Score ,Study Management ,Coma Scale ,Secondary Outcomes ,Drug Administration ,Antibiotic Treatment ,Identified Bacteria ,Primary Outcome ,Associate Editor ,Intensive Care ,Raffaele Scientific Institute ,Via Olgettina ,Interest Disclosures ,Umehara Memorial ,Thermo Fisher ,Critical Care Reviews Meeting ,